Phase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumors

被引：0
|
作者：
Toshihiko Doi
Kenji Tamura
Yuko Tanabe
Kan Yonemori
Takayuki Yoshino
Nozomu Fuse
Makoto Kodaira
Hideaki Bando
Kazuo Noguchi
Takashi Shimamoto
Atsushi Ohtsu
机构：
[1] National Cancer Center Hospital East,Exploratory Oncology Research & Clinical Trial Center
[2] National Cancer Center Hospital,undefined
[3] National Cancer Center,undefined
[4] MSD K.K.,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2015年 / 76卷
关键词：
MK-2206; pan-AKT inhibitor; Pharmacokinetics; Phase I study; Skin toxicity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：409 / 416
页数：7
相关论文
共 50 条
  • [1] Phase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumors
    Doi, Toshihiko
    Tamura, Kenji
    Tanabe, Yuko
    Yonemori, Kan
    Yoshino, Takayuki
    Fuse, Nozomu
    Kodaira, Makoto
    Bando, Hideaki
    Noguchi, Kazuo
    Shimamoto, Takashi
    Ohtsu, Atsushi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (02) : 409 - 416
  • [2] First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
    Yap, Timothy A.
    Yan, Li
    Patnaik, Amita
    Fearen, Ivy
    Olmos, David
    Papadopoulos, Kyriakos
    Baird, Richard D.
    Delgado, Liliana
    Taylor, Adekemi
    Lupinacci, Lisa
    Riisnaes, Ruth
    Pope, Lorna L.
    Heaton, Simon P.
    Thomas, George
    Garrett, Michelle D.
    Sullivan, Daniel M.
    de Bono, Johann S.
    Tolcher, Anthony W.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (35) : 4688 - 4695
  • [3] PHASE 1 STUDY OF THE SELECTIVE AKT INHIBITOR MK-2206 IN JAPANESE PATIENTS WITH ADVANCED SOLID TUMORS
    Tanabe, Y.
    Doi, T.
    Tamura, K.
    Yonemori, K.
    Kodaira, M.
    Fuse, N.
    Bando, H.
    Maeda, Y.
    Shimamoto, T.
    Ohtsu, A.
    ANNALS OF ONCOLOGY, 2012, 23 : 164 - 164
  • [4] Schedule-dependent modulation of the pharmacokinetics of MK-2206, an oral pan-AKT inhibitor: perspectives
    Nuggehally R. Srinivas
    Cancer Chemotherapy and Pharmacology, 2015, 76 : 1315 - 1316
  • [5] Schedule-dependent modulation of the pharmacokinetics of MK-2206, an oral pan-AKT inhibitor: perspectives
    Srinivas, Nuggehally R.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (06) : 1315 - 1316
  • [6] Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors
    L Rhoda Molife
    Li Yan
    Joanna Vitfell-Rasmussen
    Adriane M Zernhelt
    Daniel M Sullivan
    Philippe A Cassier
    Eric Chen
    Andrea Biondo
    Ernestina Tetteh
    Lillian L Siu
    Amita Patnaik
    Kyriakos P Papadopoulos
    Johann S de Bono
    Anthony W Tolcher
    Susan Minton
    Journal of Hematology & Oncology, 7
  • [7] Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors
    Molife, L. Rhoda
    Yan, Li
    Vitfell-Rasmussen, Joanna
    Zernhelt, Adriane M.
    Sullivan, Daniel M.
    Cassier, Philippe A.
    Chen, Eric
    Biondo, Andrea
    Tetteh, Ernestina
    Siu, Lillian L.
    Patnaik, Amita
    Papadopoulos, Kyriakos P.
    de Bono, Johann S.
    Tolcher, Anthony W.
    Minton, Susan
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2014, 7
  • [8] A phase I study of MK-2206, an oral potent allosteric Akt inhibitor (Akti), in patients (pts) with advanced solid tumor (ST)
    Tolcher, A. W.
    Yap, T. A.
    Fearen, I.
    Taylor, A.
    Carpenter, C.
    Brunetto, A. T.
    Beeram, M.
    Papadopoulos, K.
    Yan, L.
    de Bono, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [9] A phase I trial of MK-2206 and hydroxychloroquine in patients with advanced solid tumors
    Mehnert, Janice M.
    Kaveney, Amanda D.
    Malhotra, Jyoti
    Spencer, Kristen
    Portal, Daniella
    Goodin, Susan
    Tan, Antoinette R.
    Aisner, Joseph
    Moss, Rebecca A.
    Lin, Hongxia
    Bertino, Joseph R.
    Gibbon, Darlene
    Doyle, Laurence A.
    White, Eileen P.
    Stein, Mark N.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (04) : 899 - 907
  • [10] A phase I trial of MK-2206 and hydroxychloroquine in patients with advanced solid tumors
    Janice M. Mehnert
    Amanda D. Kaveney
    Jyoti Malhotra
    Kristen Spencer
    Daniella Portal
    Susan Goodin
    Antoinette R. Tan
    Joseph Aisner
    Rebecca A. Moss
    Hongxia Lin
    Joseph R. Bertino
    Darlene Gibbon
    Laurence A. Doyle
    Eileen P. White
    Mark N. Stein
    Cancer Chemotherapy and Pharmacology, 2019, 84 : 899 - 907
12345